secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mersana Therapeutics, Inc. (—)
CIK:        0001442836
Form:       8-K
Filed at:   2023-06-09T23:59:59+00:00
Accession:  0001104659-23-069929
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mersana files amendment to eliminate supermajority; shareholders reject officer exculpation at annual meeting
--------------------------------------------------------------------------------

- Amendment to eliminate supermajority voting requirement for capitalization changes filed and effective June 8, 2023.
- Stockholders approved capitalization supermajority elimination (Proposal 4): 85.3M for, 85,206 against.
- Officer exculpation amendment (Proposal 5) rejected: 68.9M for, 16.2M against.
- Advisory vote on exec compensation approved (65.7M for, 19.7M against); auditor ratification approved (88.4M for).
- Three Class III directors elected: Lawrence Alleva, David Mott, and Anna Protopapas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442836/000110465923069929/0001104659-23-069929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442836/000110465923069929/tm2318328d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-069929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer